Tributyrin for Parkinson's Disease

Tributyrin for Parkinson's Disease

Overview

Tributyrin (glyceryl tributyrate) is a triglyceride ester of butyric acid that is being investigated in a Phase 1/2 clinical trial (NCT07154511) for its potential to improve cognitive function in patients with Parkinson's Disease who have cognitive impairments. The trial is sponsored by Prabesh Kanel and aims to evaluate whether tributyrin supplementation can improve memory, thinking, and motor function in PD patients [1].

Tributyrin represents an epigenetic approach to neurodegeneration, leveraging the epigenetic-modulating properties of butyric acid to potentially restore neuronal function and protect against cognitive decline. This represents a novel therapeutic strategy that addresses the underlying epigenetic dysregulation observed in Parkinson's Disease [2].

Mechanism of Action

Butyric Acid Biology

Butyric acid (butanoic acid) is a short-chain fatty acid (SCFA) produced naturally by gut microbiota through fermentation of dietary fiber. It serves as a primary energy source for colonocytes and exerts widespread effects on systemic metabolism and immune function [3].

Key Properties of Butyric Acid:

Tributyrin for Parkinson's Disease

Overview

Tributyrin (glyceryl tributyrate) is a triglyceride ester of butyric acid that is being investigated in a Phase 1/2 clinical trial (NCT07154511) for its potential to improve cognitive function in patients with Parkinson's Disease who have cognitive impairments. The trial is sponsored by Prabesh Kanel and aims to evaluate whether tributyrin supplementation can improve memory, thinking, and motor function in PD patients [1].

Tributyrin represents an epigenetic approach to neurodegeneration, leveraging the epigenetic-modulating properties of butyric acid to potentially restore neuronal function and protect against cognitive decline. This represents a novel therapeutic strategy that addresses the underlying epigenetic dysregulation observed in Parkinson's Disease [2].

Mechanism of Action

Butyric Acid Biology

Butyric acid (butanoic acid) is a short-chain fatty acid (SCFA) produced naturally by gut microbiota through fermentation of dietary fiber. It serves as a primary energy source for colonocytes and exerts widespread effects on systemic metabolism and immune function [3].

Key Properties of Butyric Acid:

| Property | Mechanism | Therapeutic Implication |
|----------|-----------|------------------------|
| HDAC Inhibition | Class I/IIa histone deacetylase inhibition | Epigenetic regulation of neuroprotective genes |
| Energy Metabolism | Mitochondrial energy substrate | Enhanced neuronal energy production |
| Anti-inflammatory | NF-κB inhibition, Treg promotion | Reduced neuroinflammation |
| Gut-Brain Axis | SCFA signaling to brain | Systemic neuroprotective effects |
| Gene Expression | Histone acetylation | Upregulation of BDNF, antioxidant genes |

Tributyrin as a Pro-Drug

Tributyrin is a triglyceride form of butyric acid that offers several advantages over direct butyric acid administration:

Pharmacokinetic Advantages:

Epigenetic Mechanisms in Parkinson's Disease

Parkinson's Disease is associated with widespread epigenetic alterations:

Histone Modifications in PD:

• Reduced histone acetylation: Associated with transcriptional dysfunction
• HDAC overexpression: Found in PD patient brains and animal models
• Gene expression alterations: Dysregulation of neuroprotective genes

By inhibiting HDACs, tributyrin promotes:

• Increased histone acetylation at neuroprotective gene promoters
• Upregulation of brain-derived neurotrophic factor (BDNF)
• Enhanced expression of antioxidant enzymes (SOD, catalase)
• Reduced expression of pro-inflammatory mediators
• Restoration of mitochondrial function genes

Clinical Development

Phase 1/2 Trial (NCT07154511)

Trial Overview:

• Identifier: NCT07154511
• Status: Recruiting
• Sponsor: Prabesh Kanel
• Phase: Phase 1/Phase 2
• Design: Interventional
• Intervention: Tributyrin supplement

Study Population:

• Adults with Parkinson's Disease
• Presence of cognitive impairment
• Able to comply with supplementation regimen

| Domain | Assessment Tools |
|--------|-----------------|
| Cognitive Function | Standardized neuropsychological tests |
| Motor Function | Walking/balance assessments |
| Safety | Adverse event monitoring |
| Biomarkers | Optional biomarker assessments |

Rationale for Cognitive Impairment in PD

Cognitive impairment is a common non-motor symptom in Parkinson's Disease, affecting up to 50% of patients over the disease course. The underlying mechanisms include:

• Dopaminergic signaling deficits: Frontal-striatal circuit dysfunction
• Cholinergic degeneration: Basal forebrain cholinergic neuron loss
• Lewy body pathology: Cortical Lewy body deposition
• Network dysfunction: Disrupted frontoparietal networks
• Epigenetic alterations: Histone acetylation deficits

Preclinical Evidence

Butyric Acid in Neurodegeneration Models

Alzheimer's Disease Models:

• Improved memory performance in APP/PS1 mice
• Reduced amyloid plaque burden
• Enhanced synaptic plasticity
• Increased BDNF expression

• Protected dopaminergic neurons in MPTP models
• Reduced neuroinflammation
• Improved motor function
• Enhanced mitochondrial function

• HDAC inhibition in brain tissue
• Increased histone acetylation
• Upregulated neurotrophic factors
• Reduced pro-inflammatory cytokines

Human Evidence

While direct evidence in PD is limited, studies in other neurological conditions support the therapeutic potential:

• Cognitive function: Improved cognition in MCI patients
• Mood disorders: Antidepressant-like effects
• Metabolic syndrome: Improved insulin sensitivity
• Inflammatory conditions: Reduced systemic inflammation

Therapeutic Implications

Advantages of Tributyrin Approach

| Aspect | Description |
|--------|-------------|
| Novel Mechanism | Epigenetic modulation distinct from dopaminergic therapies |
| Non-dopaminergic | Addresses non-motor symptoms (cognition) |
| Disease-modifying | Potential to modify underlying pathology |
| Good Safety Profile | Naturally occurring SCFA with favorable safety |
| Oral Administration | Convenient delivery route |
| Cost-effective | Lower development costs vs. novel molecules |

Comparison with Other PD Cognitive Therapies

| Therapy | Mechanism | Status | Limitations |
|---------|-----------|--------|-------------|
| Tributyrin | HDAC inhibition | Phase 1/2 | Early stage |
| Cholinesterase Inhibitors | Acetylcholinesterase inhibition | Approved | Modest efficacy |
| Rivastigmine | AChE/BuChE inhibition | Approved | GI side effects |
| DA Agonists | Dopamine receptor activation | Approved | May worsen cognition |
| Deep Brain Stimulation | Neurostimulation | Approved | Invasive |

Combination Potential

Tributyrin may be suitable for combination with:

• Standard dopaminergic therapies (levodopa, agonists)
• Cognitive-enhancing medications
• Physical exercise programs
• Diet-based interventions (Mediterranean diet, ketogenic diet)

Safety and Tolerability

Adverse Event Profile

Butyric acid and tributyrin have demonstrated favorable safety profiles:

Common (Mild):

• Gastrointestinal discomfort
• Flatulence
• Nausea (rare)

• Headache
• Fatigue

• Allergic reactions

Contraindications and Precautions

• Pancreatic insufficiency: May affect absorption
• GI surgery: May alter absorption
• Pregnancy: Limited data
• Children: Not recommended

Drug Interactions

Tributyrin may interact with:

• HDAC inhibitors (additive effects)
• Anticoagulants (theoretical bleeding risk)
• GI motility agents (may affect absorption)

Connection to Gut-Brain Axis

Tributyrin's mechanism intersects with the gut-brain axis, an emerging area of PD research:

Gut-Brain Axis in Parkinson's Disease:

• α-Synuclein propagation from gut to brain
• Gut microbiome alterations in PD
• Intestinal permeability ("leaky gut")
• Systemic inflammation originating from gut

• Provides substrate for gut microbiota
• May improve gut barrier function
• Reduces systemic inflammation
• Modulates microbiome composition

Research Directions

Ongoing and Future Studies

Biomarker Development

Potential biomarkers for tributyrin response:

• Peripheral HDAC activity
• Inflammatory cytokines (IL-6, TNF-α)
• BDNF levels
• Microbiome composition
• Metabolomic profiles

References

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [PD Cognitive Impairment](/diseases/parkinson-disease-cognitive-impairment)
• [Epigenetic Therapies](/therapeutics/epigenetic-therapies-neurodegeneration)
• [HDAC Inhibitors](/therapeutics/histone-deacetylase-inhibitors-neurodegeneration)
• [Gut-Brain Axis](/entities/gut-brain-axis)
• [Butyric Acid Biology](/entities/butyrate)
• [BDNF in PD](/mechanisms/bdnf-signaling-neurodegeneration)
• [Parkinson's Disease Clinical Trials Index](/clinical-trials/parkinsons-disease)

External Resources

• [ClinicalTrials.gov - NCT07154511](https://clinicaltrials.gov/study/NCT07154511)
• [Parkinson's Foundation - Cognitive Changes](https://www.parkinson.org/)
• [Michael J. Fox Foundation](https://www.michaeljfox.org/)

Pathway Diagram